Special Issue

T Cells in Viral Infections

Message from the Guest Editor

T cell-based therapy has shown great potential as a more powerful approach to treating numerous diseases, including cancers and infectious and autoimmune disorders by harnessing the body's immune system. It is anticipated that responses initiated by immunotherapeutic interventions would explicitly uncover a venue of discerningly suppressing the individual disease while maintaining the rest of the immune system functionally active. Increasing knowledge in cellular immunology and the host immune response has led to the exciting development of diverse immunotherapeutic modalities, the use of non-specific immunosuppressive drugs with associated side effects, adoptive T-cell transfer-based therapy, and modulation of the local environment including the tumor microenvironment and inflammatory microenvironment to facilitate T cell immunity. Nevertheless, despite enormous advances in T cell-based therapy, the clinical efficacy and benefits remain less satisfactory due to a variety of factors that lessen anti-disease immunity. Effective strategies to bypassing these barriers should significantly improve T cell-based immunotherapy for various diseases and are thus urgently needed.

Guest Editor

Prof. Dr. Jianxun Song

Microbial Pathogenesis and Immunology Department, College of Medicine Faculty, Texas A&M University Health Science Center, Bryan, TX, USA

Deadline for manuscript submissions

closed (15 October 2022)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/94176

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).